Bristol Myers’ US/UK List Price Parity Plan For Cobenfy Leverages Trump’s MFN Concerns

 
• By Kevin Grogan and Cathy Kelly
  
Ex-US price negotiations likely will include reference to the MFN benchmark going forward. (Shutterstock)

More from Pricing Debate

More from United States